Sir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has been a triumph, starting with the against-the-odds victory over Pfizer’s charmless accountants in 2014.
The $39bn (£29bn) purchase of Alexion in 2021 looked a little over-priced at the time, but you could see how it sat well with Soriot’s sermons on the importance of backing science. The deal got AZ into the field of medicines for rare diseases, which should offer decades of growth.
